Genmab A/S
GMAB
$24.65
$0.230.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 925.00M | 715.00M | 920.51M | 816.36M | 779.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 925.00M | 715.00M | 920.51M | 816.36M | 779.00M |
| Cost of Revenue | 57.00M | 42.00M | 48.16M | 40.23M | 28.00M |
| Gross Profit | 868.00M | 673.00M | 872.35M | 776.13M | 751.00M |
| SG&A Expenses | 144.00M | 126.00M | 178.50M | 127.46M | 129.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 565.00M | 527.00M | 596.52M | 504.11M | 518.00M |
| Operating Income | 360.00M | 188.00M | 323.99M | 312.25M | 261.00M |
| Income Before Tax | 423.00M | 244.00M | 514.78M | 253.31M | 307.00M |
| Income Tax Expenses | 87.00M | 49.00M | -34.73M | 66.75M | 104.00M |
| Earnings from Continuing Operations | 336.00M | 195.00M | 549.50M | 186.55M | 203.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 336.00M | 195.00M | 549.50M | 186.55M | 203.00M |
| EBIT | 360.00M | 188.00M | 323.99M | 312.25M | 261.00M |
| EBITDA | 372.00M | 200.00M | 336.56M | 324.78M | 271.00M |
| EPS Basic | 5.44 | 0.44 | 8.65 | 2.94 | 3.15 |
| Normalized Basic EPS | 3.87 | 0.32 | 5.23 | 2.31 | 2.93 |
| EPS Diluted | 5.42 | 0.44 | 8.57 | 2.92 | 3.13 |
| Normalized Diluted EPS | 3.85 | 0.32 | 5.18 | 2.30 | 2.91 |
| Average Basic Shares Outstanding | 61.76M | 439.82M | 63.53M | 63.49M | 64.44M |
| Average Diluted Shares Outstanding | 61.99M | 441.26M | 64.15M | 63.91M | 64.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |